STOCK TITAN

Elite Pharmaceuticals Q2 revenue reaches $40.1M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Elite Pharmaceuticals Inc. reported second-quarter fiscal 2027 consolidated revenue of $40.1 million for the three months ended September 30, 2026, up $3.8 million, or approximately 10.4%, from the same period a year earlier. Income from operations was $9.9 million, an increase of $1.7 million, or approximately 21%; net income attributable to common shareholders was $17.3 million.

The company said increased revenue from its Elite-label amphetamine and naltrexone product lines primarily drove the year-over-year revenue increase. Management scheduled a conference call for November 13, 2026, at 11:30 AM EST to discuss the results and recent business developments; stockholder questions were to be submitted in advance.

2 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

How the balance works

Positive

  • Moderate pointRevenue increased approximately 10.4% to $40.1 million year over year.
  • Moderate pointIncome from operations increased approximately 21% to $9.9 million year over year.

Negative

  • None.
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Consolidated revenue $40.1 million Three months ended September 30, 2026; approximately 10.4% higher than the same period of the prior fiscal year
Revenue increase $3.8 million Approximately 10.4% compared with the same period of the prior fiscal year
Income from operations $9.9 million Second quarter of fiscal year 2027; approximately 21% higher than the same period of the prior fiscal year
Increase in income from operations $1.7 million Approximately 21% compared with the same period of the prior fiscal year
Net income attributable to common shareholders $17.3 million Second quarter of fiscal year 2027
cGMP technical
"a cGMP and DEA-registered research, development, and manufacturing facility"
cGMP (current Good Manufacturing Practice) are government-enforced quality standards that manufacturers must follow to ensure drugs, medical devices, and related products are made consistently, safely, and meet specified quality tests. For investors, cGMP compliance is like a restaurant passing health inspections: it reduces the risk of product recalls, regulatory fines, or production stoppages that can hurt revenue and company value, and it supports market access and long-term trust.
DEA-registered regulatory
"a cGMP and DEA-registered research, development, and manufacturing facility"
controlled-release medical
"oral, controlled-release drug products"
A controlled-release medicine is a drug formulation designed to release its active ingredient gradually over a set period instead of all at once. Like a slow-drip faucet that keeps a steady flow rather than a single pour, it helps maintain more stable drug levels in the body, which can affect dosing schedules, patient adherence, manufacturing complexity, regulatory review, patent life, and potential market value for companies that make or sell the product.
Consolidated revenue $40.1 million Increased by $3.8 million, or approximately 10.4%, compared with the same period of the prior fiscal year
Income from operations $9.9 million Increased by $1.7 million, or approximately 21%, compared with the same period of the prior fiscal year
Net income attributable to common shareholders $17.3 million

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was ELTP's revenue in the second quarter of fiscal 2027?

Elite reported $40.1 million in consolidated revenue for the three months ended September 30, 2026, up $3.8 million, or approximately 10.4%, from the same period of the prior fiscal year.

How much net income did ELTP report for the second quarter of fiscal 2027?

Net income attributable to common shareholders was $17.3 million for the second quarter of fiscal 2027.

What drove ELTP's second-quarter revenue increase?

The increase was primarily due to increased revenue from the Elite-label amphetamine and naltrexone product lines compared with the same period of the prior fiscal year.

When is ELTP's second-quarter results call, and when were questions due?

Management scheduled the call for November 13, 2026, at 11:30 AM EST. Financial questions were to be submitted by 7:00 PM EST on November 12, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001053369 0001053369 2026-11-12 2026-11-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

November 12, 2026

Date of Report (Date of earliest event reported)

 

ELITE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-15697   22-3542636
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)

 

165 Ludlow Avenue, Northvale, New Jersey 07647

(Address of principal executive offices)

 

(201) 750-2646

(Registrant’s telephone number, including area code)

 

 

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   ELTP   OTCQB

 

 

 

 
 

 

Item 2.02. Results of Operations and Financial Condition.

 

On November 12, 2026, Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) filed its quarterly report on Form 10-Q for the second quarter ended September 30, 2026 of fiscal year 2027, and, thereafter, issued a press release announcing its financial results for that quarter. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

 

As noted in the press release, the Company will host a conference call at 11:30 AM Eastern Standard Time (EST) on Friday, November 13, 2026, to provide a general business update. Elite will respond to various stockholder questions submitted prior to the call.

 

Conference Call Information

 

Date: November 13, 2026
Time: 11:30 AM EST
Dial-in numbers: 1-800-346-7359 (domestic)
  1-973-528-0008 (international)
Conference number: 98840
Questions: dianne@elitepharma.com
  Financial questions by 7:00 PM EST on Thursday, November 12 2026
Audio Replay: https://elite.irpass.com/events_presentations

 

Item 7.01 Regulation FD Disclosure.

 

The information disclosed in Item 2.02 above is incorporated into this Item 7.01. The information included in this Current Report on Form 8-K (including the exhibit hereto) is being furnished under Item 2.02, “Results of Operations and Financial Condition,” Item 7.01, “Regulation FD Disclosure” and Item 9.01 “Financial Statements and Exhibits” of Form 8-K. As such, the information (including the exhibit) herein shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing. This Current Report (including the exhibit hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press Release dated November 12, 2026
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: November 12, 2026 ELITE PHARMACEUTICALS, INC.
     
  By: /s/ Nasrat Hakim
    Nasrat Hakim, President and CEO

 

 

 

Exhibit 99.1

 

 

Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2027 ended September 30, 2026 and Provides Conference Call Information

 

Conference Call Scheduled for Friday, November 13, 2026 at 11:30 AM EST

 

Northvale, NJ – November 12, 2026: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB: ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the Second quarter of fiscal year 2027 ended September 30, 2026 (“Second Quarter”).

 

Consolidated revenues for the three-month period ending September 30, 2026, were $40.1 million, an increase of $3.8 million or approximately 10.4% as compared to the same period of the prior fiscal year. This increase was primarily due to increased revenues from the Elite label amphetamine and naltrexone product lines, as compared to the same period of the prior fiscal year. Income from operations were $9.9 million, an increase of $1.7 million or approximately 21%, as compared to the same period of the prior fiscal year. Net income attributable to common shareholders was $17.3 million for the Second Quarter.

 

Conference Call Information

 

Elite’s management will host a conference call to discuss the Second Quarter of Fiscal Year 2027 financial results and provide an update on recent business developments. Stockholder questions should be submitted to the company in advance of the call.

Date: November 13, 2026
Time: 11:30 AM EST
Dial-in numbers: 1-800-346-7359 (domestic)
1-973-528-0008 (international)
Conference number: 98840
Questions: dianne@elitepharma.com
Financial questions by 7:00 PM EST on Thursday, November 12, 2026
Audio Replay: https://elite.irpass.com/events_presentations

 

The financial statements can be viewed for Elite’s Second Quarter of Fiscal Year 2027 on Form 10-Q here.

 

 
 

 

About Elite Pharmaceuticals, Inc.

 

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. Elite specializes in developing, manufacturing, and distributing oral, controlled-release drug products. Elite owns multiple generic products, which it distributes nationwide under the Elite Laboratories, Inc. label. Elite operates a cGMP and DEA-registered research, development, and manufacturing facility in Northvale, NJ. For more information, visit www.elitepharma.com.

 

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA, and the actions the FDA may require of Elite to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite’s filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

 

Contact:

 

For Elite Pharmaceuticals, Inc.

Dianne Will, Investor Relations, 518-398-6222

Dianne@elitepharma.com

www.elitepharma.com

 

 

Filing Exhibits & Attachments

5 documents

Keep reading